BIOCELTIX is the first company in Europe to implement a safe, animal-friendly and scalable business technology for the therapeutic use of allogeneic stem cells in a single donor – many recipients system (…). Thanks to this, our medicines will be available immediately, “said Łukasz Bzdzion, president of the board at BIOCELTIX, during the 22nd WallStreet conference.
We invite you to watch the full interview.
